Table 3 Characteristics of 36 adult patients with tigecycline non-susecptible K. pneumoniae bacteremia

Age (years, median, IQR)

75.5, 63.5–81.7

Male sex

27 (75)

Underlying disease

 Immunosuppression^a

9 (25)

 Diabetes mellitus

18 (50)

 Chronic obstructive lung disease

5 (13.9)

 Cerebral vascular disease

10 (27.8)

 Chronic kidney disease, stage = 4 or 5

13 (36.1)

  Hemodialysis

11 (30.6)

 Malignancy

14 (38.9)

  Hematological malignancy

3 ( 8.3)

  Solid tumor

11 (30.6)

 Liver cirrhosis

3 (8.3)

Charlson comorbidity score (median, IQR)

3, 2–6

Community-acquired infections

3 ( 8.3)

Healthcare-associated infections^b

6 (16.7)

Nosocomial infections^b

27 (75)

 ICU

14 (38.9)

 Medical ward

8 (22.2)

 Surgical ward

5 (13.9)

Polymicrobial infection

2 (5.6)

Antibiotic exposure in the past 30 days, ≥3 days

 Any

29 (80.6)

 Tigecycline

13 (36.1)

 Glycopeptides

11 (30.6)

 β-lactams plus β-lactamase inhibitors

12 (33.3)

 First- and second-generation cephalosporins

11 (30.6)

 Third- or fourth-generation cephalosporins

10 (27.8)

 Carbapenem

9 (25)

 Fluoroquinolones

8 (22.2)

 Metronidazole

9 (25)

Ward, duration of stay and devices at the time of bacteremia

 Acquired after ICU >48 h

14 (38.9)

 Days of hospitalization before bacteremia (median, IQR)

48, 18–82

 Urinary catheter

17 (47.2)

 Central venous catheter

23 (63.9)

 Mechanical ventilation

18 (50)

Pitt bacteremia score (mean ± SD)

4 ± 4

APACHE II score (mean ± SD)

23 ± 10

Infection sources and clinical syndrome

 Pneumonia

10 (27.8)

 Intra-abdominal infection other than biliary-tract infection

5 (13.9)

 Biliary-tract infection

7 (19.4)

 Skin and soft-tissue infection

2 (5.6)

 Catheter infection

1 (2.8)

 Urinary-tract infection

1 (2.8)

 Unknown primary focus

10 (27.8)

Appropriate antibiotic treatment

17 (47.2)

Outcome

 Presentation with septic shock

19 (52.8)

 Requiring admission to ICU after bacteremia

19 (52.8)

 In-hospital death

17 (47.2)

 28-day mortality

14 (38.9)